Microbiota intestinal: impacto en la enfermedad metabólica
Main Article Content
Abstract
La microbiota del intestino cumple una serie de funciones metabólicas e inmunológicas en el ser humano, lo que permite buen estado de salud. Se conoce actualmente las implicaciones que tiene la alteración de la microbiota intestinal y la respuesta adversa del hospedero a estos cambios (disbiosis) sobre las enfermedades metabólicas. El sobrepeso y la obesidad constituyen factores de riesgo para un gran número de enfermedades crónicas, como el síndrome metabólico, la diabetes, las enfermedades cardiovasculares y algunos tipos de cáncer. Es así como el desequilibrio en la composición de la microbiota intestinal se han asociado a una mayor susceptibilidad a las infecciones y los trastornos de base inmunológica y, recientemente, también a la resistencia a la insulina y al aumento del peso corporal. En relación a la evidencia actual, resulta importante investigar los efectos en la modificación de la microbiota intestinal, mediante el uso alimentos funcionales probióticos y prebióticos, a fin de intervenir y prevenir el desarrollo de la obesidad y las alteraciones metabólicas.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
Alteraciones de la microbiota intestinal y la respuesta adversa del hospedero a estos cambios J.F. Petrosino, S. Highlander, R.A. Luna, et al. Metagenomic pyrosequencing and microbial identification. Clin Chem, 55 (2009), pp. 856-866 http://dx.doi.org/10.1373/clinchem.2008.107565 | Medline
Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabol-ic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Cardiol Rev. 2005; 13(6): 322-327.
Ferrer B, Dalmau J. Reflexiones sobre el síndrome metabólico. Acta Pediatr Esp. 2008; 66(3): 77-82.
Reid G, Sanders ME, Gaskins HR, Gibson GR, Mercenier A, Rastall R, et al. New scientific paradigms for probiotics and prebiotics. JClin Gastr. 2003; 37: 105-118.
Sanz Y, Nadal I, Sánchez E. Probiotics as drugs against human gastrointestinal infections. Rec Pat Anti-Infect Drug Disc. 2007; 2: 148-156.
Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol. 2006; 6: 772-783.
Cani PD, Bibiloni R, Knauf C, Waget A, Neyrinck AM, Delzenne NM, et al. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes. 2008; 57: 1.470-1.481.
Hooper LV, Midtvedt T, Gordon JI. How hostmicrobial interactions shape the nutrient environment of the mammalian intestine. Annu Rev Nutr 2002; 22: 283-307. 2.
Mercenier A, Pavan S, Pot B. Probiotics as biotherapeutic agents: present knowledge and future prospects. Curr Pharm Desing 2003; 9: 175-191. 3.
Fanaro S, Chierici R, Guerrini P, Vigi V. Intestinal microflora in early infancy: composition and development. Acta Pae-diatr supl 2003; 441: 48-55.
Collins MD, Gibson GR. Probiotics, prebiotics, and synbiotics: approaches for modulating the microbial ecology of the gut. Am J Clin Nutr 1999; 69: 1.052S-1.057S.
Guarner F, Malagelada JR. Gut flora in health and disease. Lancet 2003; 361: 512-519.
Schiffrin EJ, Blum S. Interactions between the microbiota and the intestinal mucosa. Eur J Clin Nutr. 2002 Aug;56 Suppl 3:S60-4.
Hara AM, Shanahan F.. The gut flora as a forgotten organ. EMBO Rep. 2006 Jul;7(7):688-93.
Weng M, Walker W. Bacterial colonization, probiotics, and clinical disease. J Pediatr. 2006 nov; 149(5): S 107-S114.
Toole PW, Claesson MJ. Gut microbiota : changes throughout the lifespan from infancy to elderly. Int Dairy J. 2010 Apr; 20(4): 281-91.
Hooper LV. Bacterial contributions to mammalian gut development. Trends Microbiol. 2004;12(3):129-34.
DiBaise JK, Zhang H, Crowell MD, Krajmalnik-Brown R, Decker GA, Rittmann BE. Gut microbiota and its possible rela-tionship with obesity. Mayo Clin Proc. 2008;83(4):460-9.
Macpherson AJ, Hunziker L, McCoy K, Lamarre A. IgA responses in the intestinal mucosa against pathogenic and non-pathogenic microorganisms. Microbes Infect. 2001;3(12):1021-35.
Cebra JJ, Jiang HQ, Boiko N, Tlaskalova-Hogenova H. The role of mucosal microbiota in the development, maintenance, and pathologies of the mucosal immune system. In: Mestecky J, Lamm ME, Strober W, editors. Mucosal immunology. 3rd ed. Burlington, MA : Elsevier; 2005. p. 335-368.
Montalto M, D’Onofrio F, et al. Intestinal microbiota and its functions. Dig Liver Dis suppl. 2009 Jul; 3(2):30-4
Ouwehand AC, Vaughan EE, editors. Gastrointestinal microbiology. New York : Informa Healthcare; 2006.
Neish AS. Microbes in gastrointestinal health and disease. Gastroenterology. 2009 Jan; 136(1):65-80.
Savage DC. Mucosal microbiota. In: Mestecky J, Lamm ME, Strober W, editors. Mucosal immunology. 3rd ed. Burlington, MA : Elsevier; 2005, p. 19-33.
Tungland BC, Meyer D. Nondigestible oligoand polysaccharides (dietary fiber): their physiology and role in human health and food. Comprehensive Reviews in Food Science and Food Safety 2002; 1: 73-92.
Teitelbaum JE, Walker WA. Nutritional impact of pre- and probiotics as protective gastrointestinal organisms. Annu Rev Nutr 2002; 22: 107-138.
Mahida YR. Microbial-gut interactions in health and disease. Epithelial cell responses. Best Pract Res Clin Gastroenterol. 2004 Apr; 18(2):241-53.
Brandtzaeg P, Kiyono H, Pabst R, Russell MW. Terminology: nomenclature of mucosa-associated lymphoid tissue. Mucosal Immunol. 2008;1(1):31-7.
O’Hara AM, Shanahan F.. The gut flora as a forgotten organ. EMBO Rep. 2006 Jul;7(7):688-93.
Thompson-Chagoyán OC, Maldonado J, Gil A. Aetiology of inflammatory bowel disease (ibd): role of intestinal microbiota and gut-associated lymphoid tissue immune response. Clin Nutr. 2005 Jun; 24(3):339-52.
Denise K. Importance of microbial colonization of the gut in early life to the development of immunity. Mutat Res. 2007; 622 (1-2), 58–69.
Raoult D. Obesity pandemics and the modification of digestive bacterial flora. Eur J Clin MicrobiolDis. 2008;27(8):631-4.
46. Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Microbial ecology: human gut microbes associated with obesity. Nature. 2006;444(7122):1022-3.
Ley RE, Bäckhed F, Turnbaugh P, Lozupone CA, Knight RD, Gordon JI. Obesity alters gut microbial ecology. Proc Natl Acad Sci USA. 2005;102(31):11070-5
Duncan SH, Belenguer A, Holtrop G, Johnstone AM, Flint HJ, Lobley GE. Reduced dietary intake of carbohydrates by obese subjects results in decreased concentrations of butyrate and butyrate-producing bacteria in feces. Appl Environ Microbiol. 2007;73(4):1073-8.
Backhed F, Ding H, Wang T, et al: The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci USA 2004; 1 01: 1 5718–15723.
Bäckhed F, Manchester JK, Semenkovich CF, Gordon JI: Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. Proc Natl Acad Sci USA 2007; 1 04: 979– 984.
Iwamoto Y, Nishimura F, Nakagawa M, et al: The effect of antimicrobial periodontal treatment on circulating tumor ne-crosis factor-alpha and glycated hemoglobin level in patients with type 2 diabetes. J Periodontol 2001; 7 2: 774–778.
143. Hotamisligil GS. Inflammation and endoplasmic reticulum stress in obesity and diabetes. Int J Obes. 2008;32(Suppl 7):S52-4.
Sanz Y, Santacruz A, Dalmau J. Influencia de la mi-crobiota intestinal en la obesidad y las alteraciones del metabolismo. Acta Pediatr Esp 2009;67:437-42.
Cani PD, Amar J, Iglesias MA, Poggi M, Knauf C, Bastelica D, et al. Metabolic endotoxaemia initiates obesity and insulin resistance. Diabetes 2007;56:1761-72.
. Amar J, Burcelin R, Ruidavets J, Cani P, Fauvel J, Alessi M, et al. Energy intake is associated with endotoxemia in appar-ently healthy men. Am J Clin Nutr 2008; 87: 1219-23
Drucker DJ. Biological actions and therapeutic potential of the glucagon-like peptides. Gastroenterol 2002;122:531-44.
Morales P, Brignardello J, Gotteland M. La micro-biota intestinal: Un nuevo actor en el desarrollo de la obesidad. Rev Med Chil 2010;138:1020-7.
Speliotes EK et al. Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index 2010 Nov;42 (11):937-48. doi: 10.1038/ng.686. Epub 2010 Oct 10.
Almeida J, Galhenage S, Yu J, Kurtovic J, Riordan SM. Gut flora and bacterial translocation in chronic liver disease. World J Gastroenterol. 2006 Mar 14;12(10):1493-502
Quigley EM. Bacteria: a new player in gastrointestinal motility disorders? infections, bacterial overgrowth, and pro-biotics. Gastroenterol Clin North Am. 2007 Sep;36(3):735-48
Tiihonen K, Ouwehand AC, Rautonen N. Human intestinal microbiota and healthy ageing. Ageing Res Rev. 2010 Apr;9(2):107-16.
Schrezenmeir J, Vrese M. Probiotics, prebiotics, and synbiotics-approaching a definition. Am J Clin Nutr 2001;73:361S-4S.
Ma X, Hua J, Li Z. Probiotics improve high fat diet-induced hepatic steatosis and insulin resistance by increasing hepatic NKT cells. J Hepatol 2008; 49:821-30
Jenkins D, Kendall C, Vuksan V. Inulin, oligo-fructose, and intestinal function. J Nutr 1999; 129:1431S-33S.